A mutation in the DNA polymerase accessory factor of herpes simplex virus 1 restores viral DNA replication in the presence of raltegravir

Journal of Virology

Volumn 88, Issue 19, 2014, Pages 11121-11129

  Zhou, Bin ^a,b   Yang, Kui ^a   Wills, Elizabeth ^a   Tang, Liang ^c   Baines, Joel D ^a  

^a Department of Microbiology and Immunology Cornell University ^*  (United States)

^b NANJING AGRICULTURAL UNIVERSITY   (China)

^c UNIVERSITY OF KANSAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA POLYMERASE; DNA POLYMERASE ACCESSORY FACTOR; RALTEGRAVIR; UNCLASSIFIED DRUG; 2 PYRROLIDONE DERIVATIVE; ANTIVIRUS AGENT; DNA DIRECTED DNA POLYMERASE; DNA POLYMERASE, SIMPLEXVIRUS; EXODEOXYRIBONUCLEASE; VIRUS DNA; VIRUS PROTEIN;

ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; DNA REPLICATION; GENE SEQUENCE; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN CYTOMEGALOVIRUS; NONHUMAN; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; REAL TIME POLYMERASE CHAIN REACTION; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE; ANIMAL; ANTIVIRAL RESISTANCE; CELL LINE; CHEMICAL STRUCTURE; CHLOROCEBUS AETHIOPS; CYTOMEGALOVIRUS; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; HUMAN; MOUSE; MUROMEGALOVIRUS; MUTATION;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CERCOPITHECUS AETHIOPS; CYTOMEGALOVIRUS; DNA REPLICATION; DNA, VIRAL; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE, VIRAL; EXODEOXYRIBONUCLEASES; GENE EXPRESSION REGULATION, VIRAL; HERPESVIRUS 1, HUMAN; HERPESVIRUS 2, HUMAN; HUMANS; MICE; MODELS, MOLECULAR; MUROMEGALOVIRUS; MUTATION; PYRROLIDINONES; TRANSCRIPTION, GENETIC; VIRAL PROTEINS;

EID: 84906979349     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01540-14     Document Type: Article

References (41)

1. Conway JF, Homa FL. 2011. Nucleocapsid structure, assembly and DNA packaging of herpes simplex virus, p 175-193. In Weller SK (ed), Alphaherpesviruses. Caister Academic Press, Norfolk, United Kingdom.
2. Baines JD. 2011. Herpes simplex virus capsid assembly and DNA packaging: a present and future antiviral drug target. Trends Microbiol. 19: 606-613. http://dx.doi.org/10.1016/j.tim.2011.09.001.
3. L33 of herpes simplex virus 1 form a complex in infected cells. J. Virol. 76:4785-4791. http://dx.doi .org/10.1128/JVI.76.10.4785-4791.2002.
4. Yu D, Weller SK. 1998. Genetic analysis of the UL 15 gene locus for the putative terminase of herpes simplex virus type 1. Virology 243:32-44. http://dx.doi.org/10.1006/viro.1998.9041.
5. Yang K, Homa F, Baines JD. 2007. Putative terminase subunits of herpes simplex virus 1 form a complex in the cytoplasm and interact with portal protein in the nucleus. J. Virol. 81:6419-6433. http://dx.doi.org/10.1128 /JVI.00047-07.
6. Goldner T, Hewlett G, Ettischer N, Ruebsamen-Schaeff H, Zimmermann H, Lischka P. 2011. The novel anti-cytomegalovirus compound AIC246 inhibits HCMV replication through a specific antiviral mechanism that involves the viral terminase. J. Virol. 85:10884-10893. http://dx .doi.org/10.1128/JVI.05265-11.
7. Selvarajan Sigamani S, Zhao H, Kamau YN, Baines JD, Tang L. 2013. The structure of the herpes simplex virus DNA-packaging terminase pUL15 nuclease domain suggests an evolutionary lineage among eukaryotic and prokaryotic viruses. J. Virol. 87:7140-7148. http://dx.doi.org/10 .1128/JVI.00311-13.
8. Nadal M, Mas PJ, Blanco AG, Arnan C, Sola` M, Hart DJ, Coll M. 2010. Structure and inhibition of herpesvirus DNA packaging terminase nuclease domain. Proc. Natl. Acad. Sci. U. S. A. 107:16078-16083. http://dx .doi.org/10.1073/pnas.1007144107.
9. Grinsztejn B, Nguyen BY, Katlama C, Gatell JM, Lazzarin A, Vittecoq D, Gonzalez CJ, Chen J, Harvey CM, Isaacs RD. 2007. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatmentexperienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 369:1261-1269. http://dx.doi.org/10 .1016/S0140-6736(07)60597-2.
10. Summa V, Petrocchi A, Bonelli F, Crescenzi B, Donghi M, Ferrara M, Fiore F, Gardelli C, Gonzalez PO, Hazuda DJ, Jones P, Kinzel O, Laufer R, Monteagudo E, Muraglia E, Nizi E, Orvieto F, Pace P, Pescatore G, Scarpelli R, Stillmock K, Witmer MV, Rowley M. 2008. Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. J. Med. Chem. 51:5843-5855. http://dx.doi.org/10.1021/jm800245z.
11. Hazuda DJ, Felock P, Witmer M, Wolfe A, Stillmock K, Grobler JA, Espeseth A, Gabryelski L, Schleif W, Blau C, Miller MD. 2000. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 287:646-650. http://dx.doi.org/10.1126/science.287 .5453.646.
12. Hare S, Vos AM, Clayton RF, Thuring JW, Cummings MD, Cherepanov P. 2010. Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance. Proc. Natl. Acad. Sci. U. S. A. 107: 20057-20062. http://dx.doi.org/10.1073/pnas.1010246107.
13. Hare S, Gupta SS, Valkov E, Engelman A, Cherepanov P. 2010. Retroviral intasome assembly and inhibition of DNA strand transfer. Nature 464:232-236. http://dx.doi.org/10.1038/nature08784.
14. Ejercito PM, Kieff ED, Roizman B. 1968. Characterization of herpes simplex virus strains differing in their effects on social behavior of infected cells. J. Gen. Virol. 2:357-364. http://dx.doi.org/10.1099/0022-1317-2-3-357.
15. Tanaka M, Kagawa H, Yamanashi Y, Sata T, Kawaguchi Y. 2003. Construction of an excisable bacterial artificial chromosome containing a full-length infectious clone of herpes simplex virus type 1: viruses reconstituted from the clone exhibit wild-type properties in vitro and in vivo. J. Virol. 77:1382-1391. http://dx.doi.org/10.1128/JVI.77.2.1382-1391.2003.
16. Yang K, Poon AP, Roizman B, Baines JD. 2008. Temperature-sensitive mutations in the putative herpes simplex virus type 1 terminase subunits pUL15 and pUL33 preclude viral DNA cleavage/packaging and interaction with pUL28 at the nonpermissive temperature. J. Virol. 82:487-494. http://dx.doi.org/10.1128/JVI.01875-07.
17. Homa FL, Otal TM, Glorioso JC, Levine M. 1986. Transcriptional control signals of a herpes simplex virus type 1 late (g2) gene lie within bases -34 to +124 relative to the 5′ terminus of the mRNA. Mol. Cell. Biol. 6:3652-3666.
18. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 25:402-408. http://dx.doi.org/10.1006/meth.2001.1262.
19. Yang K, Baines JD. 2011. Selection of HSV capsids for envelopment involves interaction between capsid surface components pUL31, pUL17, and pUL25. Proc. Natl. Acad. Sci. U. S. A. 108:14276-14281. http://dx.doi .org/10.1073/pnas.1108564108.
20. Ram JL, Karim AS, Sendler ED, Kato I. 2011. Strategy for microbiome analysis using 16S rRNA gene sequence analysis on the Illumina sequencing platform. Syst. Biol. Reprod. Med. 57:162-170. http://dx.doi.org/10 .3109/19396368.2011.555598.
21. Robinson JT, Thorvaldsdottir H, Winckler W, Guttman M, Lander ES, Getz G, Mesirov JP. 2011. Integrative genomics viewer. Nat. Biotechnol. 29:24-26. http://dx.doi.org/10.1038/nbt.1754.
22. Tischer BK, von Einem J, Kaufer B, Osterrieder N. 2006. Two-step RED-mediated recombination for versatile high-efficiency markerless DNA manipulation in Escherichia coli. Biotechniques 40:191-197. http: //dx.doi.org/10.2144/000112096.
23. Liang L, Tanaka M, Kawaguchi Y, Baines JD. 2004. Cell lines that support replication of a novel herpes simplex 1 UL31 deletion mutant can properly target UL34 protein to the nuclear rim in the absence of UL31. Virology 329:68-76. http://dx.doi.org/10.1016/j.virol.2004.07.030.
24. Jacobson JG, Yang K, Baines JD, Homa FL. 2006. Linker insertion mutations in the herpes simplex virus type 1 UL28 gene: effects on UL28 interaction with UL15 and UL33 and identification of a second-site mutation in the UL15 gene that suppresses a lethal UL28 mutation. J. Virol. 80:12312-12323. http://dx.doi.org/10.1128/JVI.01766-06.
25. Szpara ML, Parsons L, Enquist LW. 2010. Sequence variability in clinical and laboratory isolates of herpes simplex virus 1 reveals new mutations. J. Virol. 84:5303-5313. http://dx.doi.org/10.1128/JVI.00312-10.
26. Hernandez TR, Lehman IR. 1990. Functional interaction between the herpes simplex-1 DNA polymerase and UL42 protein. J. Biol. Chem. 265: 11227-11232.
27. Ruyechan WT, Weir AC. 1984. Interaction with nucleic acids and stimulation of the viral DNA polymerase by the herpes simplex virus type 1 major DNA-binding protein. J. Virol. 52:727-733.
28. Davison AJ. 1992. Channel catfish virus: a new type of herpesvirus. Virology 186:9-14. http://dx.doi.org/10.1016/0042-6822(92)90056-U.
29. Lamberti C, Weller SK. 1998. The herpes simplex virus type 1 cleavage/ packaging protein, UL32, is involved in efficient localization of capsids to replication compartments. J. Virol. 72:2463-2473.
30. Gottlieb J, Marcy AI, Coen DM, Challberg MD. 1990. The herpes simplex virus 1 UL42 gene product: a subunit of DNA polymerase that functions to increase processivity. J. Virol. 64:5976-5987.
31. Sacks WR, Greene CC, Aschman DP, Schaffer PA. 1985. Herpes simplex virus type 1 ICP27 is an essential regulatory protein. J. Virol. 55:796-805.
32. Zuccola HJ, Filman DJ, Coen DM, Hogle JM. 2000. The crystal structure of an unusual processivity factor, herpes simplex virus UL42, bound to the C terminus of its cognate polymerase. Mol. Cell 5:267-278. http://dx.doi .org/10.1016/S1097-2765(00)80422-0.
33. Wu CA, Nelson NJ, McGeoch DJ, Challberg MD. 1988. Identification of herpes simplex virus type 1 genes required for origin-dependent DNA synthesis. J. Virol. 62:435-443.
34. Malet I, Delelis O, Valantin MA, Montes B, Soulie C, Wirden M, Tchertanov L, Peytavin G, Reynes J, Mouscadet JF, Katlama C, Calvez V, Marcelin AG. 2008. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob. Agents Chemother. 52:1351-1358. http://dx.doi .org/10.1128/AAC.01228-07.
35. Malet I, Gimferrer AL, Artese A, Costa G, Parrotta L, Alcaro S, Delelis O, Tmeizeh A, Katlama C, Valantin MA, Ceccherini-Silberstein F, Calvez V, Marcelin AG. 2014. New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors. J. Antimicrob. Chemother. 69:2118-2122. http://dx.doi.org/10.1093/jac/dku095.
36. Gilbert C, Bestman-Smith J, Boivin G. 2002. Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Drug Resist. Updat. 5:88-114. http://dx.doi.org/10.1016/S1368-7646(02)00021-3.
37. Burrel S, Deback C, Agut H, Boutolleau D. 2010. Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals. Antimicrob. Agents Chemother. 54:4833-4842. http://dx.doi.org/10.1128/AAC.00669-10.
38. Fischer L, Laib SK, Jahn G, Hamprecht K, Gohring K. 2013. Generation and characterization of a GCV resistant HCMV UL97-mutation and a drug sensitive UL54-mutation. Antiviral Res. 100:575-577. http://dx.doi .org/10.1016/j.antiviral.2013.09.026.
39. Bestman-Smith J, Schmit I, Papadopoulou B, Boivin G. 2001. Highly reliable heterologous system for evaluating resistance of clinical herpes simplex virus isolates to nucleoside analogues. J. Virol. 75:3105-3110. http://dx.doi.org/10.1128/JVI.75.7.3105-3110.2001.
40. Bestman-Smith J, Boivin G. 2003. Drug resistance patterns of recombinant herpes simplex virus DNA polymerase mutants generated with a set of overlapping cosmids and plasmids. J. Virol. 77:7820-7829. http://dx .doi.org/10.1128/JVI.77.14.7820-7829.2003.
41. Drouot E, Piret J, Boivin G. 2013. Novel method based on "en passant" mutagenesis coupled with a Gaussia luciferase reporter assay for studying the combined effects of human cytomegalovirus mutations. J. Clin. Microbiol. 51:3216-3224. http://dx.doi.org/10.1128/JCM.01275-13.